Legal Representation
Attorney
Julianne Abelman
USPTO Deadlines
Next Deadline
695 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-06-29)
Due Date
June 29, 2027
Grace Period Ends
December 29, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
47 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 2, 2023 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
Jun 2, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Jun 2, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Jun 2, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Jun 2, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Jun 2, 2023 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
Jun 2, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Jun 29, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
May 28, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
May 27, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
May 26, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
May 26, 2021 | DPCC | D | DIVISIONAL PROCESSING COMPLETE | Loading... |
May 26, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
May 6, 2021 | DRRR | I | DIVISIONAL REQUEST RECEIVED | Loading... |
May 6, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
May 6, 2021 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED | Loading... |
May 6, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
Mar 3, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Mar 1, 2021 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Mar 1, 2021 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Mar 1, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Sep 1, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Jul 23, 2020 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
Jun 26, 2020 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED | Loading... |
Jun 24, 2020 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
Jun 2, 2020 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
Feb 11, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
Jan 14, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Jan 14, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Dec 25, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Dec 12, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Dec 11, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Dec 11, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Dec 11, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jun 11, 2019 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Jun 11, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jun 11, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jun 4, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jun 4, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jun 4, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jun 4, 2019 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Dec 6, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Dec 6, 2018 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Dec 6, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Dec 3, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Aug 25, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Aug 20, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
Business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, large molecule development, antibody drug conjugates and clinical development services; consulting services in the field of medical practice management for others; business consulting and management in the field of clinical trials, namely, providing information management services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies; business management consulting services in the field of pharmaceuticals drug development; none of the aforesaid services relating to gel imaging and gel analysis applications
First Use Anywhere:
Aug 31, 2004
First Use in Commerce:
Aug 31, 2004
Class 042
Scientific research and custom synthesis; scientific and clinical research in the field of medicine, pharmaceutical, nutraceuticals; scientific research and development; custom design and development of chemical reagents and biochemical assays; laboratory testing; laboratory testing services for research and development purposes; testing of pharmaceuticals; chemical engineering; drug discovery services; pharmaceutical drug development services; pharmaceutical products development; development of pharmaceutical preparations and medicines; scientific study and research in the field of reproduction, husbandry, and general health of animal; biotechnology research for determining the neuronal survival of molecules in animal models; research and development services in the field of antibodies, antibody technology; custom design and development of chemical reagents and biochemical assays; design, engineering, research, development and testing services in the field of polymeric materials, polymer synthesis, and materials customization for medical, scientific, and technological applications; toxicology services; toxicity analysis; toxicity testing for research purposes; conducting clinical trials; conducting clinical trials for scientific research for others; conducting clinical trials for pharmaceutical products; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; DNA analysis services for scientific research purposes; laboratory research in the field of gene expression; blood analysis services for scientific research purposes; analysis of human tissues for medical research; scientific services relating to the isolation and cultivation of human tissues and cells for research purposes; preparation of reports relating to scientific and technical research; analysis in the field of molecular biology; contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific and medical laboratory services; services of a chemical and/or biological laboratory; laboratory research services relating to pharmaceuticals; research and development and consultation related thereto in the field of antibodies, antibody technology, chemistry, bioinformatics, biomedical devices, biologics, biotechnology, biotherapeutics, biology, biochemical preparations, cell lines, cheminformatics, genetics and genetic engineering, gene expression systems, in vitro research, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, ophthalmic preparations, pharmacogenetics, pharmacokinetics, pharmacology, pharmaceuticals, polymers, peptide synthesis, protein, and solid state characterization; toxicokinetic analysis and toxicology services; scientific and technological services, namely, scientific research, development, analysis, testing, engineering, extraction, synthesis, purification and production in the field of antibodies, active pharmaceutical ingredients (API), biomolecules, cell bank characterization, chirality, chromosome aberration, clinical chemistry, cloning vector, cyclotides, DNA, flow cytometry, gas chromatography mass spectrometry, genes, immuno-pharmaceuticals, in vitro irritation, large molecule, liquid chromatography mass spectrometry, microbials, monomers, nanoparticles, natural products, peptides, proteins, RNA, supercritical fluid chromatography, small molecules and vaccines; none of the aforesaid services relating to gel imaging and gel analysis applications, and none of the aforesaid services in the field of agriculture, horticulture and forestry
First Use Anywhere:
Aug 31, 2004
First Use in Commerce:
Aug 31, 2004
Additional Information
Design Mark
The mark consists of the word "Syngene" in stylized font.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
035
042